Oneness Biotech Co Ltd (TWO:4743) — Market Cap & Net Worth
Market Cap & Net Worth: Oneness Biotech Co Ltd (4743)
Oneness Biotech Co Ltd (TWO:4743) has a market capitalization of $801.88 Million (NT$25.45 Billion) as of May 2, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #10144 globally and #325 in its home market, demonstrating a 0.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oneness Biotech Co Ltd's stock price NT$53.20 by its total outstanding shares 478423000 (478.42 Million). Analyse how efficiently does Oneness Biotech Co Ltd generate cash to see how efficiently the company converts income to cash.
Oneness Biotech Co Ltd Market Cap History: 2015 to 2026
Oneness Biotech Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $517.08 Million to $801.88 Million (5.23% CAGR).
Oneness Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oneness Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.16x
Oneness Biotech Co Ltd's market cap is 11.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $517.08 Million | $7.84 Million | -$93.02 Million | 65.95x | N/A |
| 2016 | $454.19 Million | $5.70 Million | -$14.26 Million | 79.64x | N/A |
| 2017 | $268.80 Million | $2.59 Million | -$155.45 Million | 103.91x | N/A |
| 2018 | $346.27 Million | $18.86 Million | -$235.44 Million | 18.36x | N/A |
| 2019 | $389.30 Million | $13.47 Million | -$328.46 Million | 28.89x | N/A |
| 2020 | $3.19 Billion | $41.60 Million | -$251.68 Million | 76.70x | N/A |
| 2021 | $3.81 Billion | $65.77 Million | -$412.82 Million | 57.89x | N/A |
| 2022 | $3.25 Billion | $1.07 Billion | $359.98 Million | 3.05x | 9.03x |
| 2023 | $2.93 Billion | $86.78 Million | -$1.31 Billion | 33.78x | N/A |
| 2024 | $1.32 Billion | $117.93 Million | -$1.17 Billion | 11.16x | N/A |
Competitor Companies of 4743 by Market Capitalization
Companies near Oneness Biotech Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Oneness Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Oneness Biotech Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Oneness Biotech Co Ltd's market cap moved from $517.08 Million to $ 801.88 Million, with a yearly change of 5.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$801.88 Million | -4.32% |
| 2025 | NT$838.06 Million | -36.31% |
| 2024 | NT$1.32 Billion | -55.12% |
| 2023 | NT$2.93 Billion | -9.82% |
| 2022 | NT$3.25 Billion | -14.61% |
| 2021 | NT$3.81 Billion | +19.29% |
| 2020 | NT$3.19 Billion | +719.73% |
| 2019 | NT$389.30 Million | +12.43% |
| 2018 | NT$346.27 Million | +28.82% |
| 2017 | NT$268.80 Million | -40.82% |
| 2016 | NT$454.19 Million | -12.16% |
| 2015 | NT$517.08 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Oneness Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $801.88 Million USD |
| MoneyControl | $801.88 Million USD |
| MarketWatch | $801.88 Million USD |
| marketcap.company | $801.88 Million USD |
| Reuters | $801.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more